Exploiting bacteria for cancer immunotherapy
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
RetractedPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“For example, approximately 40–65% of patients with melanoma 2 and 45–85% of those with non-small-cell lung cancer (NSCLC) 3–5 have primary resistance to immune-checkpoint inhibitor (ICI)-based therapy despite these tumour types being among the most responsive to such agents.”
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“These findings are in keeping with metagenomics sequencing data from cohorts of patients with melanoma indicating that Ruminococcaceae, Eubacterium and Alistipes are associated with a favourable response to ICIs whereas Clostridium and Enterocloster are associated with ICI resistance 244 .”
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“Activation of innate immune cells by bacteria within the TME triggers subsequent adaptive immune responses, for example, via activation of the IL-23–IL-17 axis 54 , TNF receptor signalling 55,56 , IL-6 signalling 57 , and/or signal transducer and activator of transcription 3 (STAT3) signalling 58 .”
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“The composition of the gut microbiota has been shown to influence the response of patients with cancer to immunotherapy 244,245 .”
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718 · cited 1×
“Additionally, this bacterium selectively recruits myeloid-derived suppressor cells (MDSCs) to tumours in mouse models of CRC, leading to immunosuppression in the TME and promoting metastasis 61 .”
Rubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G., & Han, Y. W. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.012 · Cited by 2,476 · cited 14×
“Other bacteria (for example, Hungatella hathewayi and Fusobacterium nucleatum , which are also implicated in CRC development) induce epigenetic modification of the host genome through upregulation of DNA methyltransferases via unknown mechanisms, thereby promoting hypermethylation and silencing of tumour-suppressor ge…”
InfluentialThe human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464 · cited 7×
“Data from patients with metastatic melanoma indicate tumour enrichment for the Clostridium genus at baseline in ICI responders, whereas Gardnerella vaginalis was enriched in tumours from non-responders 13 , implying that manipulation of the microbiota might improve immunotherapeutic efficacy.”
InfluentialFusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817 · cited 1×
“For example, in patients with PDAC, intratumoural Gammaproteobacteria expressing cytidine deaminase promote resistance to gemcitabine by metabolizing and inactivating this drug 77 .”
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 2×
“Initial studies of this approach have shown that resistance to anti-PD-1 antibodies can be overcome in some patients with ICI-refractory metastatic melanoma through FMT from anti-PD-1-responsive donors 246,247 (Table 2).”
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689 · cited 1×
“Activation of innate immune cells by bacteria within the TME triggers subsequent adaptive immune responses, for example, via activation of the IL-23–IL-17 axis 54 , TNF receptor signalling 55,56 , IL-6 signalling 57 , and/or signal transducer and activator of transcription 3 (STAT3) signalling 58 .”
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577 · cited 14×
“Oral pathogens associated with an increased risk of developing PDAC, such as Aggregatibacter actinomycetem-comitans , are also implicated in gemcitabine resistance according to their expression of this enzyme 78 .”
InfluentialGarrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1134 · Cited by 1,400
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392 · cited 1×
“The human microbiota has important implications for tumorigenesis and cancer therapy and, although the gut microbiota has been the primary focus of research in these areas 6–8 , insights into the existence and pathological relevance of intratumoural microbiota are beginning to emerge 9–12 .”
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · cited 2×
“Activation of innate immune cells by bacteria within the TME triggers subsequent adaptive immune responses, for example, via activation of the IL-23–IL-17 axis 54 , TNF receptor signalling 55,56 , IL-6 signalling 57 , and/or signal transducer and activator of transcription 3 (STAT3) signalling 58 .”
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Branzk, N., Lubojemska, A., Hardison, S. E., Wang, Q., Gutierrez, M. G., Brown, G. D., & Papayannopoulos, V. (2014) · Nature Immunology · doi:10.1038/ni.2987 · Cited by 1,037
Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., Li, H., Bai, H., Liu, X., Zhang, Y., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.027 · Cited by 981
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 4×
“Bacterial genera tested for such purposes in preclinical studies and clinical trials include Streptococcus , Clostridium , Bifidobacterium , Listeria , Escherichia , Lactobacillus and Salmonella 23,26,88 (Supplementary Table 2).”
InfluentialAllen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100050 · Cited by 826
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821 · cited 7×
“with the oncologist regarding the timing of administration to avoid compromising the efficacy of BCIT or increasing the infection risk 25 .”
InfluentialSynchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777 · cited 1×
“The human microbiota has important implications for tumorigenesis and cancer therapy and, although the gut microbiota has been the primary focus of research in these areas 6–8 , insights into the existence and pathological relevance of intratumoural microbiota are beginning to emerge 9–12 .”
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724 · cited 1×
“154), eliciting durable tumour regression and systemic antitumour immunity in preclinical models.”
Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647 · cited 2×
“153) or CD47 (ref.”
Metabolic modulation of tumours with engineered bacteria for immunotherapy
Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., et al. (2021) · Nature · doi:10.1038/s41586-021-04003-2 · Cited by 619 · cited 2×
“A meta-bolically engineered strain of EcN has been developed to produce high levels of l-arginine within tumours via feedback-resistant biosynthesis from ammonia, a metabolic waste product 174 .”
Goodwin, A. C., Shields, C. E. D., Wu, S., Huso, D. L., Wu, X., Murray-Stewart, T. R., Hacker-Prietz, A., Rabizadeh, S., Woster, P. M., Sears, C. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010203108 · Cited by 612
Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
Self-citationFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526 · cited 12×
“Consequently, FMT is currently being explored in multiple clinical trials as a supplementary therapy to improve the clinical efficacy of ICIs.”
InfluentialSystemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16079-x · Cited by 513 · cited 1×
“such as butyrate and propionate, are associated with increased proportions of regulatory T (T reg ) cells among circulating CD4 + T cells and resistance to anti-CTLA4 antibodies in patients with cancer 66 .”
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496 · cited 2×
“Such bacteria contribute to tumour development and/or malignant progression via various mechanisms 9,10,12,30 (Supplementary Figure 1).”
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460 · cited 2×
“However, advances in synthetic genetic circuits have enabled more precise control over gene expression, yielding novel functionalities and sophisticated control mechanisms 178,196–198 .”
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458
Identification of bacteria-derived HLA-bound peptides in melanoma
Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03368-8 · Cited by 457 · cited 1×
“Additionally, intratu-moural bacteria-derived peptides presented by tumour cells can activate tumour-specific T cell responses 72 .”
Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4
Hu, B., Elinav, E., Huber, S., Booth, C. J., Strowig, T., Jin, C., Eisenbarth, S. C., & Flavell, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016814108 · Cited by 452
Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M., & Kanneganti, T.-D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002046 · Cited by 411
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396 · cited 2×
“Notably, peptide epitopes mimicking TSAs have been identified in Bifidobacterium breve 73 and Enterococcus hirae harbouring a specific prophage 74 , with T cell cross-reactivity for these antigens resulting in enhanced anti-tumour responses and immunotherapeutic activity in mouse models.”
Live biotherapeutic products: The importance of a defined regulatory framework
Cordaillat-Simmons, M., Rouanet, A., & Pot, B. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0437-6 · Cited by 328
Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Atreya, R., & Neurath, M. F. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:187 · Cited by 324 · cited 1×
“Activation of innate immune cells by bacteria within the TME triggers subsequent adaptive immune responses, for example, via activation of the IL-23–IL-17 axis 54 , TNF receptor signalling 55,56 , IL-6 signalling 57 , and/or signal transducer and activator of transcription 3 (STAT3) signalling 58 .”
Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318
Akolpoglu, M. B., Alapan, Y., Dogan, N. O., Baltaci, S. F., Yasa, O., Aybar Tural, G., & Sitti, M. (2022) · Science Advances · doi:10.1126/sciadv.abo6163 · Cited by 293 · cited 1×
“…composed of motile E. coli bacteria carrying magnetic nanoparticles loaded with photothermal and chemotherapeutic agents can navigate through biological matrices and colonize tumour spheroids under magnetic guidance prior to releasing the cargo drugs in response to a near-infrared stimulus 222 .”
Structure Elucidation of Colibactin and Its DNA Cross-Links
Xue, M., Kim, C. S., Healy, A. R., Wernke, K. M., Wang, Z., Frischling, M. C., Shine, E. E., Wang, W., Herzon, S. B., & Crawford, J. M. (2019) · Science · doi:10.1126/science.aax2685 · Cited by 257
The microbiome and the hallmarks of cancer
Fulbright, L. E., Ellermann, M., & Arthur, J. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006480 · Cited by 164 · cited 1×
“of the diversity and functional importance of the microbiome of solid tumours 13,14,16,19–21 .”
Quorum-sensing Salmonella selectively trigger protein expression within tumors
Swofford, C. A., Van Dessel, N., & Forbes, N. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414558112 · Cited by 145
Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium
Guo, Y., Chen, Y., Liu, X., Min, J.-J., Tan, W., & Zheng, J. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.033 · Cited by 124
Self-citationThe Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V., & Wargo, J. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.007 · Cited by 98 · cited 1×
“For over a century, bacteria have been known to reside within tumour tissues 13,27 .”
Spreafico, A., Heirali, A. A., Araujo, D. V., Tan, T. J., Oliva, M., Schneeberger, P. H. H., Chen, B., Wong, M. K., Stayner, L.-A., Hansen, A. R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.011 · Cited by 96 · cited 2×
“tested as an alternative to FMT in the phase II–III MET4-IO trial 249 .”
Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models
Lee, C., Wu, C., & Shiau, A. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.626 · Cited by 93 · cited 1×
“Salmonella choleraesuis strains designed to transfer genes encoding the anti-angiogenic factors endostatin or thrombospondin 1 have demonstrated antitumour effects via inhibition of new blood vessel formation in several mouse models 95,125 .”
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Zhu, L., Song, G., Zhang, W., Wu, Y., Chen, Y., Song, J., Wang, D., Li, G., Tang, B. Z., & Li, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-57533-y · Cited by 63
“In recent years, biological carriers, including cells, bacteria, and viruses 37,38 ,haveattractedconsiderableattentionintumortherapydue to their ability to naturally target and accumulate within tumor tissues 8,39 – 44 .”
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“274 For instance, Redenti et al. engineered the probiotic Escherichia coli Nissle 1917 as an antitumor vaccine platform optimized for enhanced production and cytosolic delivery of neoepitope peptides, with increased susceptibility to blood clearance and phagocytosis.”
Metadata
- Authors
- Kwon, S.-Y., Thi-Thu Ngo, H., Son, J., Hong, Y., & Min, J.-J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2024-06-05
- Volume
- 21
- Issue
- 8
- Pages
- 569-589
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4399362619
- Cited by
- 201
- References
- 58
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.